水合他克莫司（FK506）：治疗重症肌无力的疗效及反应者的选择
Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis.
作者信息
Wakata Nobuo, Saito Toyokazu, Tanaka Sachiko, Hirano Toshihiko, Oka Kitaro
机构信息
Fourth Department of Internal Medicine, Toho University School of Medicine, 2-17-6 Oohashi, Meguro-ku, Tokyo 153-8515, Japan.
出版信息
Clin Neurol Neurosurg. 2003 Dec;106(1):5-8. doi: 10.1016/s0303-8467(03)00046-5.
Tacrolimus hydrate (FK506) reduces myasthenic symptoms due to its immunosuppressive properties. We studied the therapeutic effects of FK506 and noted improvement in 7 of 13 myasthenic patients on the clinical muscle test (myasthenia gravis, MG score). Two other patients with relapsing ocular symptoms improved. We also examined patient sensitivity to FK506, but could not predict such sensitivity before FK506 treatment in the present study.
水合他克莫司（FK506）因其免疫抑制特性可减轻肌无力症状。我们研究了FK506的治疗效果，在临床肌肉测试（重症肌无力，MG评分）中，13例肌无力患者中有7例症状得到改善。另外2例有复发性眼部症状的患者病情也有所改善。我们还检测了患者对FK506的敏感性，但在本研究中，在FK506治疗前无法预测这种敏感性。
Zotero 插件